From Bench to Bedside: Applications to Drug Discovery and Development Eric Neumann W3C HCLSIG co-chair Teranode Corporation HCLSIG F2F Cambridge MA.

Slides:



Advertisements
Similar presentations
1 Intermountain Healthcare Clinical Genetics Institute Marc S. Williams, M.D. Director Grant M. Wood Senior IT Strategist Introduction to HL7 Clinical.
Advertisements

Using DAML format for representation and integration of complex gene networks: implications in novel drug discovery K. Baclawski Northeastern University.
Improving the sharing of NICE content via syndication: what the future could hold Andrew Fenton CIO NICE 20 March 2014.
Semantic Web for Life Sciences W3C BOF 2005 ISMB.
Protocol Author Process People Technology
The Open Innovation Center Susie Stephens, Principal Research Scientist, Eli Lilly.
December 14, FDA Advisory Committee for Pharmaceutical Science Nonclinical Studies Subcommittee Efficient advancement to clinical trials Jack A.
1 Pharmaceutical Challenges for the Semantic Web.
Influencing Change in Research, Treatment Protocols, and New Drug Development.
CUHP Cambridge University Health Partners (CUHP) unites a world-leading University and three high- performing NHS Foundation Trusts centred on the Cambridge.
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Working with FDA: Biological Products and Clinical Development Critical Path.
Bioinformatics: a Multidisciplinary Challenge Ron Y. Pinter Dept. of Computer Science Technion March 12, 2003.
Knowledge Commons: The Case of the Biopharmaceutical Industry Arti K. Rai Duke Law School.
Nanotechnology in Drug Discovery- Development and Delivery
Linked2Safety Project (FP7-ICT – 5.3) A NEXT-GENERATION, SECURE LINKED DATA MEDICAL INFORMATION SPACE FOR SEMANTICALLY-INTERCONNECTING ELECTRONIC.
Discovery of new medicines through new models of collaboration Simon Ward Professor of Medicinal Chemistry & Director of Translational Drug Discovery Group.
ICARE Member Reports ETP seeks to improve incentives and encourage commercial investment in new therapies. (Treatments reach patients only by commercial.
Medical Informatics Basics
Stages of drug development
Leveraging the Electronic Health Record for Clinical Research John P. Glaser, PhD Vice President and CIO Partners HealthCare July 21, 2008.
“Put the Power of Predictive Analytics in the Hands of Clinical Researchers” Filippos Katsampouris Marketing Manager Healthcare & Pharmaceutical Accounts.
Pharmaceutical Epistemology Jim Golden, Ph.D. Global Lead, Healthcare Data Analytics Accenture
Clinical Research Training
Building a Roadmap for Research IT John Brussolo Research IT Program Director September 6, 2012 © 2012 The Regents of the University of Michigan.
Johns Hopkins Technology Transfer 1 Translational Biomedical Research: Moving Discovery from Academic Centers to the Community Translational Biomedical.
Stefan Franzén Introduction to clinical trials.
A substance used in the diagnosis, treatment, or prevention of a disease or as a component of a medication A substance used in the diagnosis, treatment,
Applications of Computers in pharmacy
Advancing translational research with the Semantic Web Ruttenberg, Clark, Bug, Samwald, Bodenreider, Chen, Doherty, Forsberg, Gao, Kashyap, Kinoshita,
Business Value of SW in Drug Discovery Eric Neumann, W3C HCLSIG co-chair Teranode Corporation F2F Cambridge MA.
Managing Medical R&D Defining and Realizing Clinical and Commercial Value David J. Wierz Senior Director Commercial Investment & Pricing Strategy Wyeth-Ayerst.
Integrated Biomedical Information for Better Health Workprogramme Call 4 IST Conference- Networking Session.
SUPPORTING R&D IN LIFE SCIENCES DIAA ABDELRAHMAN /10/2014.
What is an Ontology? An ontology is a specification of a conceptualization that is designed for reuse across multiple applications and implementations.
Single Patient Use of Investigational Anticancer Agents: An Industry Perspective Gerard T. Kennealey, MD Vice President, Clinical Research, Oncology AstraZeneca.
6/4/20161 Commitment & Efforts Toward Translational Science Subtitle Placeholder.
ADVANCED DB SYSTEMS BIOMEDICAL ENGINEERING. Index INTRODUCTION  BIOMEDICAL ENGINEERING  B.E. DATASETS APPLICATIONS  DATA MINING ON FDA DATABASE  ONTOLOGY-BASED.
Developing medicines for the future and why it is challenging Angela Milne.
BioPaths-Catalyze Drug Discovery, Development and Clinical Research
Privacy Symposium / HIPAA Summit
Pathology Visions Conference Giri Iyer General Manager, Strategic Development Integrated IT Solutions 10/22/2007 Digital Pathology HCIT Visions – A GE.
BBN Technologies Copyright 2009 Slide 1 The S*QL Plugin for Cytoscape Visual Analytics on the Web of Linked Data Rusty (Robert J.) Bobrow Jeff Berliner,
12/7/2015Page 1 Service-enabling Biomedical Research Enterprise Chapter 5 B. Ramamurthy.
Rachel Liao, PhD Coordinator of the Clinical Working Group and the BRCA Challenge demonstration project for the Global Alliance for Genomics and Health.
Chapter Thirteen Copyright, John Wiley and Sons, Inc. Chapter Thirteen three Learning Concepts – Chapter Understand the increasing benefits and challenges.
Topic 3A SEMANTIC INTEROPERABILITY: REUSE OF EHR DATA Mats Sundgren.
Partnering With Industry for Clinical Research Luke Lin, MD, and Ralf Schnall.
Clinical research data interoperbility Shared names meeting, Boston, Bosse Andersson (AstraZeneca R&D Lund) Kerstin Forsberg (AstraZeneca R&D.
Mt. Hood. IOM Report: 10 Years After & More Coming Mitch Greenlick, Ph.D. Oregon State Representative April 21, 2010.
Clinical Research Informatics [CRI]. Informatics, defined generally as the intersection of information and computer science with a health-related discipline,
GENOMICS TO COMBAT RESISTANCE AGAINST ANTIBIOTICS IN COMMUNITY-ACQUIRED LRTI IN EUROPE (GRACE) H. Goossens (Coordinator), K. Loens (Manager), M. Ieven.
Biomedical Informatics and Health. What is “Biomedical Informatics”?
Gwendolyn Ryals, Look at Me Artwork from The Creative Center Janey Shin, Director, Real World Evidence Government Affairs and Market Access CADTH Symposium.
Patient Engagement throughout the Biopharmaceutical Lifecycle: Tips for Effective Patient Advocate/Industry Collaboration to Improve Patient Access and.
Informatics for Scientific Data Bio-informatics and Medical Informatics Week 9 Lecture notes INF 380E: Perspectives on Information.
The opportunities and challenges of sharing genomics data with the pharmaceutical industry Shahid Hanif, Head of Health Data & Outcomes, ABPI DNA digest.
A substance used in the diagnosis, treatment, or prevention of a disease or as a component of a medication recognized or defined by the U.S. Food, Drug,
1 Promotion in Management and Research Tracks in Industry Magdalena Alonso-Galicia, PhD Cardiovascular Diseases Department Merck Research Laboratories.
Semantic Web - caBIG Abstract: 21st century biomedical research is driven by massive amounts of data: automated technologies generate hundreds of.
W3C Semantic Web for Health Care and Life Sciences Interest Group
NCT: Gaining Medical Insights and Enhancing Care for Cancer Patients with SAP HANA® Organization National Center for Tumor Diseases (NCT) Heidelberg, part.
W3C Semantic Web for HealthCare and Life Sciences Interest Group
FP6 Priority 1, Life Sciences Genomics and Biotechnology for Health
Harnessing the Semantic Web to Answer Scientific Questions:
Sponsored by the University of Southampton
Gestora brasileiro focada exclusivamente na área da saúde.
Finland, a Global Testbed for Personalized Cancer Research?
Semantic Interoperability
W3C HCLS Task Force on Drug Safety and Efficacy
FP6 Priority 1, Life Sciences Genomics and Biotechnology for Health
Presentation transcript:

From Bench to Bedside: Applications to Drug Discovery and Development Eric Neumann W3C HCLSIG co-chair Teranode Corporation HCLSIG F2F Cambridge MA

Knowledge “ --is the human capacity (both potential and actual) to take effective action in varied and uncertain situations. ”

Drug Innovation and the Technology Gap Need to utilize Knowledge more effectively

Drug R&D Trends from Innovation or Stagnation, FDA Report March 2004

New Regulatory Issues Confronting Pharmaceuticals from Innovation or Stagnation, FDA Report March 2004 Tox/Efficacy ADME Optim

Translational Medicine translate Enable physicians to more effectively translate relevant findings and hypotheses into therapies for human health blending Support the blending of huge volumes of clinical research and phenotypic data with genomic research data knowledge Apply that knowledge to patients and finally make individualized, preventative medicine a reality for diseases that have a genetic basis

Role of Informatics John Glaser, CIO Partners Healthcare Providing high quality and efficient health care isn't possible anymore without a sophisticated marriage of information technology and state-of-the-art science. Bringing these together to inform patient care is a tremendous undertaking… the full array of new information provided by genomic research must be harnessed and made real for doctors and patients A Framework for conducting clinical research in and across large multidisciplinary academic medical centers is designed to establish a "new" biomedicine to "fully exploits the fruit of the genomic revolution for clinical practice and allows clinical care to be leveraged to advance basic biological research.

Challenges for Drug D&D Counteracting the legacy of “Silos” How to break away from the DD “conveyor belt model” to the “Translation model” –gaining and sharing insights throughout the process The Benefit of New Targets for New Diseases How to best identify safety and efficacy issues early on, so that cost and failure are reduced A D 3 Knowledge-base: Drugability and Safety

Drug Discovery & Development Knowledge Qualified Targets Lead Generation Toxicity & Safety Biomarkers Pharmacogenomics Clinical Trials Molecular Mechanisms Lead Optimization KDKD

Drug Discovery & Development Knowledge Qualified Targets Lead Generation Toxicity & Safety Biomarkers Pharmacogenomics Clinical Trials Molecular Mechanisms Lead Optimization Launch

Communities and Interoperability Semantic interoperability is directly tied to CoP:  “Within a community or domain, relative homogeneity reduces interoperability challenges. Heterogeneity increases as one moves outside of a focal community/domain, and interoperability is likely [to be] more costly and difficult to achieve” Moen, 2001  Meanings encoded in a schema are usually useful for only one (original) community - difficult to extend to others!  Database utility more difficult if group is heterogeneous

Multiple Ontologies Used Together Drug target ontology FOAF Patent ontology OMIM Person Group Chemical entity Disease SNP BioPAX UniProt Extant ontologies Protein Under development Bridge concept UMLS Disease Polymorphisms PubChem

Potential Linked Clinical Ontologies Clinical Trials ontology RCRIM (HL7) Genomics CDISC IRB Applications Molecules Clinical Obs ICD10 Pathways (BioPAX) Disease Models Extant ontologies Mechanisms Under development Bridge concept SNOMED Disease Descriptions Tox

Drug Safety Knowledge Human Hepato-Toxicity Study Toxicity Indication Hepato-Toxicity Lens Genomic Profile Standards set by Regulatory Agencies To be part of NDA (New Drug Applications) How will Reviewers be empowered to handle such large amaount sof new data?

CDISC and the Semantic Web? Reduce the need to write data parsers to any CDISC XML Schema Make use of ontologies and terminologies directly using RDF Easier inclusion of Genomic data Use Semantic Lenses for Reviewers Easier acceptance by industry with their current technologies

Developing Standards Design Implementation Exchange

Developing Standards Design Implementation Semantic Web-based Specifications Exchange

Support Full Information Integration Integration: integrate and manage data from sources, EDC systems, Clinical Data Management Systems, labs and CROs Analysis and reporting: Accurately and timely analytical reports from study data, for use in decision making; easier results sharing with researchers and reviewers Discovery: Use expanding research information as a knowledge base for rapid investigations into critical drug safety issues, new marketing claims, and identify product-line extensions.

Thank You